Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment  by Saito, Yukihito et al.
General
Thoracic Surgery
Pulmonary metastasectomy for 165 patients with colorectal
carcinoma: A prognostic assessment
Yukihito Saito, MD,a Hideyasu Omiya, MD,a Keijiro Kohno, MD,b Takanobu Kobayashi, MD,c Kazumi Itoi, MD,d
Masami Teramachi, MD,e Masato Sasaki, MD,f Hitoyuki Suzuki, MD,g Hitoji Takao, MD,h and Masaharu Nakade, MD,b
for the Kansai Clinical Oncology Group (Japan)
Dr Saito
Objective: The purpose of this study was to analyze our entire experience with
pulmonary resection for metastatic colorectal carcinoma to determine prognostic
factors and critically evaluate the potential role of extended metastasectomy.
Methods: We analyzed the postoperative survival of 165 patients who underwent
curative pulmonary surgery at eight institutions in the Kansai region of western
Japan (Kansai Clinical Oncology Group) from 1990 to 2000.
Results: Overall survivals at 5 and 10 years were 39.6% and 37.2%, respectively.
Cumulative survival of patients who underwent simultaneous bilateral metastasec-
tomy was significantly lower than that of the patients who underwent unilateral
metastasectomy or sequential bilateral metastasectomy (P  .048). Five-year sur-
vival was 53.6% for patients without hilar or mediastinal lymph node metastasis,
versus 6.2% at 4 years for patients with metastases (P  .001). Five-year survival
of patients with a prethoracotomy carcinoembryonic antigen level less than 10
ng/mL was 42.7%, versus 15.1% at 4 years for patients with a carcinoembryonic
antigen level 10 ng/mL or greater (P  .0001). Twenty-one patients underwent a
second or third thoracotomy for recurrent colorectal carcinoma. Overall 5-year
survival from the date of the second thoracotomy was 52.1%. The 34.1% 10-year
survival for the 26 patients with hepatic metastasis resected before thoracotomy did
not differ significantly from that of patients without hepatic metastases (P  .38).
Conclusions: The status of the hilar or mediastinal lymph nodes and prethoracotomy
carcinoembryonic antigen level were significant independent prognostic factors.
Patients with pulmonary metastases potentially benefit from pulmonary metastasec-
tomy even when there is a history of solitary liver metastasis. Careful follow-up is
warranted, because patients with recurrent pulmonary metastases can undergo
repeat thoracotomy with acceptable long-term survival. Simultaneous bilateral me-
tastasectomy confers no survival benefit. Prospective studies may determine the
significance of this type of pulmonary metastasectomy.
Pulmonary resection for metastatic colorectal carcinoma was first per-formed by Blalock1 in 1944. In 1965, Thomford and coworkers2reported an experience with surgical resection of pulmonary metas-tases from various malignancies. They mentioned that surgical treat-ment might not be indicated in patients with metastasis in organs otherthan the lung such as the liver, or with simultaneous pulmonary
metastases. They reported that indications for pulmonary metastasectomy include
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control of the primary site, no other distant metastatic dis-
ease than the lung, a technically feasible operation, and
adequate cardiopulmonary reserve of the patient. Since that
time, however, extended pulmonary metastasectomy has
become practical in patients with bilateral pulmonary me-
tastases or with distant metastasis such as a solitary liver
metastasis. The eligibility criteria for pulmonary metasta-
sectomy proposed by Thomford have been extensively
modified. Operative approaches have also changed to im-
prove the resectability of pulmonary metastases, from uni-
lateral thoracotomy to median sternotomy, transsternal bi-
lateral thoracotomy (“clamshell” thoracotomy), and video-
assisted thoracic surgery. More recently, an increasing
number of patients undergo polysurgery (repeat thoracoto-
mies). However, the potential role of extended metastasec-
tomy has not been critically evaluated. The value of an
aggressive surgical approach for the patients with bilateral
lung metastases or with solitary liver metastases is contro-
versial.
The purpose of this review was to analyze our entire
experience with pulmonary resection for metastatic colorec-
tal carcinoma in an attempt to answer the following ques-
tions: What are potential prognostic factors for patients
undergoing pulmonary metastasectomy? Is there significant
prognostic value in performing extended simultaneous pul-
monary metastasectomy in patients with bilateral lung me-
tastases? Is pulmonary metastasectomy indicated in patients
who have localized extrapulmonary disease, such as solitary
liver metastasis, if it has been resected or treated before
thoracotomy? What is the role of repeat thoracotomy for
recurrent metastatic colorectal carcinoma?
Patients and Methods
Between January 1, 1990, and December 31, 2000, a total of 165
patients underwent curative pulmonary resection for metastatic
colorectal carcinoma at eight institutions in the Kansai region of
western Japan (Kansai Clinical Oncology Group). Resection was
considered curative if all known pulmonary nodules were removed
at thoracotomy. Patients who had complete resection of all known
pulmonary disease were included in this study. Patients who had
pulmonary biopsy only were excluded. The record of each patient
was reviewed for age and sex, disease-free interval, prethora-
cotomy serum carcinoembryonic antigen (CEA) level, number and
maximum diameter of the nodules, operative procedures and ex-
tent of pulmonary resection, presence of hilar or mediastinal lymph
node metastasis, number of pulmonary metastasectomy, and du-
ration of survival. When multiple metastases were present, the
largest diameter was recorded. Operative mortality included pa-
tients who died within the first 30 days after thoracotomy and those
who died later but during the same hospitalization. Survival was
calculated from the time of first metastasectomy to the last date
follow-up. Statistical calculations were carried out with StatView
software (SAS Institute, Inc, Cary, NC). The actuarial overall
survivals were analyzed by the Kaplan-Meier method, and differ-
ences in their distributions were evaluated by the log-rank test. The
Cox proportional hazards models was used for multivariate anal-
ysis.
Results
There were 97 men and 68 women. Median age was 61.6
years (range 33-84 years). Thirty-seven patients (22.4%)
were 70 years old or older. The primary colorectal neoplasm
was a solitary adenocarcinoma in all patients and was lo-
cated in the colon in 70 patients (42.4%) and in the rectum
in 95 (57.6%). All patients were evaluated for local recur-
rence of the colorectal carcinoma. Barium enema, endos-
copy, and abdominal computed tomography were the pro-
cedures most commonly used. Bone and brain scans were
performed if there were clinical signs suggestive of metas-
tases in these areas. The median interval between colorectal
resection and lung resection was 28.4 months (range 0-111
months). Seventy-eight patients had a tumor-free interval of
less than 2 years. Conventional chest computed tomography
revealed a solitary pulmonary nodule in 104 patients
(63.0%), multiple unilateral nodules in 37 (22.4%), and
bilateral nodules in 24 (14.6%). The CEA level was mea-
sured in 108 patients and found to be elevated in 44.
All pulmonary resections were performed at a Kansai
Clinical Oncology Group institution. Pulmonary resection
followed colon resection in 163 patients; 2 patients, how-
ever, had initial lung resection that led to the subsequent
diagnosis of a colorectal carcinoma. Lateral thoracotomy
was performed in 147 patients, median sternotomy was
performed in 17 patients, and clamshell thoracotomy was
performed in patient. Six patients with simultaneous bilat-
eral metastases underwent staged thoracotomies for bilateral
pulmonary metastasectomy. Wedge resection was done in
103 patients. Thirty-seven patients underwent lobectomy, 4
underwent bilobectomy, 3 underwent pneumonectomy, and
18 underwent lobectomy combined with wedge excision. At
the operation, pulmonary metastases were unilateral in 141
patients (79 right and 62 left) and bilateral in 24. A total of
104 patients had solitary metastases, 23 had two metastases,
and 38 had three or more. Median diameter of the metasta-
ses was 25 mm (range 3-100 mm). Twenty-six patients had
liver metastases, which were resected before pulmonary
metastasectomy. Hilar or mediastinal lymph nodes were
dissected or sampled in 138 patients (Table 1).
There were no postoperative deaths in our series. Meta-
static colorectal carcinoma recurred in 102 patients (61.8%).
Recurrence was limited to the lungs in 53 patients, the
abdomen in 13, the brain in 7, the bone in 3, the mediastinal
lymph node in 2, and to other locations in 3. Recurrence
occurred in multiple organ systems in 21 patients, all of
whom had lung involvement. Altogether, recurrence in-
volved the lung in 74 patients (72.5% of those with recur-
rence). Sixty-one patients currently are alive. Deaths of the
remaining 104 patients resulted from recurrent colorectal
carcinoma in 102 cases and unknown causes in 2.
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Mean follow-up was 56.5 months (range 5-135 months).
Overall survivals at 5 and 10 years were 39.6% and 37.2%,
respectively (Figure 1, Table 2). Survival was not influ-
enced by age or sex. Likewise, 5-year survival for the 78
patients with a disease-free interval of less than 2 years was
35.1% and did not differ significantly from the 42.0%
observed for the 87 patients with a tumor-free interval of
greater than 2 years.
The size of the metastasis, when patients were divided
into those with tumors less than 20 mm in maximum diam-
eter and those with tumors 20 mm or more, was not asso-
ciated with a statistical difference in 5-year survival. There
was no significant difference in the survival of the lobec-
tomy group (lobectomy and lobectomy with wedge resec-
tion) and limited resection group (segmental and wedge
resection), with survivals of 22.2% and 47.6%, respectively,
at 10 years (P .282). However, the cumulative survival of
patients who underwent simultaneous bilateral metastasec-
tomy was significantly lower than that of patients who
underwent unilateral metastasectomy or sequential bilateral
metastasectomy (P  .048, Figure 2). Five-year survival
was 42.6% for patients with solitary metastases, versus
35.7% for patients with two or more metastases (P  .043,
Figure 3).
Hilar or mediastinal lymph nodes were dissected or sam-
pled in 138 patients, revealing metastases in 20 patients.
Five-year survival was 48.5% for the patients without hilar
or mediastinal lymph node metastasis, versus 6.2% at 4
years for the patients with metastases (P  .001, Figure 4).
Five-year survival for the 81 patients with a prethora-
cotomy CEA level less than 10 ng/mL was 42.7%, versus
15.1% at 4 years for the 27 patients with a CEA level 10
ng/mL or greater (P .0001, Figure 5). More important, all
27 patients who had an elevated prethoracotomy CEA level
had recurrence of colorectal carcinoma after thoracotomy.
Only 4 patients survived for longer than 3 years.
The number of pulmonary metastases, mode of opera-
tion, lymph node metastasis, and serum CEA level influ-
enced survival.
Twenty-three patients underwent a second or third tho-
racotomy for recurrent colorectal cancer (second 19 pa-
tients, third 4 patients). At the time of second thoracotomy,
a wedge excision was performed in 18 patients and lobec-
tomy was performed in 3. The median interval between the
first and second pulmonary resections was 14 months (range
TABLE 1. Patient features
Age (y, mean and range) 61.6 (33-84)
Sex
Male 97
Female 68
Site of primary lesion
Colon 70
Rectum 95
Disease-free interval (no.)
0 mo 9
1-11 mo 25
12-23 mo 44
24-35 mo 40
36 mo 47
Pulmonary metastases (no.)
1 104
2 23
3 38
Approach (no.)
Unilateral
Thoracotomy 124
Video-assisted thoracoscopic surgery 6
Bilateral
Sequential thoracotomy 17
Simultaneous
Sternotomy 17
Clamshell 1
Resection
Wedge or segment 103 (86/17)
Lobe 59
Pneumonectomy 3
Diseased nodes
N0 118
N1-2 20
Not sampled 27
Chemotherapy
Postoperative 63
None 102
Operations (no.)
1 142
2 19
3 4
Prethoracotomy CEA level
Normal ( 5 ng/mL) 64
Abnormal ( 5 ng/mL) 44
Not measured 57
Figure 1. Pulmonary metastasectomy for colorectal carcinoma.
Overall survival.
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1-55 months). The median interval between the second and
third pulmonary resections was 12 months (range 2-18
months). There were no major postoperative complications
and no operative deaths. Five-year survival for all 23 pa-
tients from the date of the second thoracotomy was 52.1%.
Eight patients (38.1%) were living without recurrence more
than 3 years after the second lung resection. Four patients
underwent a third pulmonary resection for recurrent carci-
noma. One of them is alive 9 years after the third thoracot-
omy without evidence of carcinoma.
The presence of hepatic metastases was not an unfavor-
able prognostic factor. The 34.1% 10-year survival ob-
served for the 26 patients with hepatic metastasis resected
before thoracotomy did not differ significantly from the
40.6% survival observed in the 139 patients without hepatic
metastases (P  .38).
The potential prognostic factors were tested by univari-
ate analysis (Table 2). Mode of operation, number of pul-
monary metastases, prethoracotomy CEA level, and status
of hilar or mediastinal lymph nodes were found to be
significant prognostic factors. All the remaining factors
listed in Table 1 were not prognostic factors. Table 2 shows
the results of multivariate analysis. Status of hilar or medi-
astinal lymph nodes and prethoracotomy CEA level were
the characteristics that retained significant independent
prognostic impact (Table 3).
TABLE 2. Survivals and univariate analysis of prognostic factors of 165 patients undergoing pulmonary metastasectomy
Variables Patients 5-y survival (%) 10-y survival (%) P value
Overall 165 39.6 37.2
Sex
Male 97 45.5 42.3 .1900
Female 68 24.7 — (24.7% at 9-y)
Age
50 y 24 22.2 — (22.2% at 6-y) .4458
50 y 141 41.4 38.7
Location of primary carcinoma
Colon 70 34.5 — (34.5% at 8 y) .6847
Rectum 95 42.4 38.6
Disease free interval
24 mo 78 35.1 35.1 .5289
24 mo 87 42.0 — (37.8% at 9 y)
Maximum tumor size
 20 mm 57 44.7 44.7 .5921
20 mm 108 38.3 35.6
Pulmonary metastases
Single 104 42.6 39.4 .0434
Multiple 61 35.7 — (35.7% at 7 y)
Operative procedure
Wedge or segmental 103 47.6 47.6 .2819
Lobectomy 59 27.8 22.2
Pneumonectomy 3 33.3 — (33.3% at 6 y)
Mode of operation
Unilateral or sequential 147 416. 39.0 .0483
Bilateral (simultaneous) 18 — (16.2% at 4 y)
Operation
Single 142 36.2 33.2 .3908
Repeat 23 54.6 54.6
Prethoracotomy CEA
10 ng/mL 81 42.7 42.7 .0001
10 ng/mL 27 — (15.1% at 4 y)
Hilar or mediastinal lymph node metastases
Negative 118 48.5 45.5 .001
Positive 20 — (6.2% at 4 y)
Postoperative chemotherapy
Yes 63 34.1 34.1 .3376
No 102 43.5 38.6
Hepatic metastases
Resected before thoracotomy 26 34.1 34.1 .3846
None 139 40.6 37.5
General Thoracic Surgery Saito et al
1010 The Journal of Thoracic and Cardiovascular Surgery ● November 2002
G
TS
Discussion
To date, no effective chemotherapeutic treatment is avail-
able for colorectal carcinoma metastatic to the lung. Con-
sequently, resection of pulmonary metastases has been ac-
cepted as appropriate therapy by many surgeons.3
In our patients, there were no operative or postoperative
deaths regardless of age. Therefore, age alone should not be
a contraindication to resection.
Limited wedge excision remains our procedure of first
choice for metastatic colorectal carcinoma. Mortality was
zero after this procedure, and long-term survival was similar
to that seen with more extensive resections of lung, such as
lobectomy.
Median sternotomy is a convenient operative approach
for patients with bilateral pulmonary lesions. However, a
median sternotomy alone is not recommended in patients
with simultaneous bilateral multiple pulmonary metastases,
because the approach limits removal of all of the metastases.
Remaining lesions after metastasectomy by median sternot-
omy, which we previously performed without endoscopic
surgical assistance, could be one reason for the poor prog-
nosis of patients with bilateral multiple metastases.
On the other hand, lateral thoracotomy, which we have
done, places no limitation on removal of metastatic lesions
because of sufficient operation area relative to that seen with
median sternotomy. This also may be one reason why
Figure 2. Pulmonary metastasectomy for colorectal carcinoma.
Mode of operation and survival.
Figure 3. Pulmonary metastasectomy for colorectal carcinoma.
Single versus multiple metastases and survival.
Figure 4. Pulmonary metastasectomy for colorectal carcinoma.
Absence versus presence of metastasis and survival.
Figure 5. Pulmonary metastasectomy for colorectal carcinoma.
CEA less than 10 ng/mL versus 10 ng/mL or more and survival.
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patients who underwent simultaneous bilateral metastasec-
tomy had significantly lower survival than did patients who
underwent unilateral or sequentially bilateral thoracotomy.
The survival of patients with bilateral multiple pulmonary
metastases could be improved by detecting small metastatic
foci before thoracotomy and completely removing all met-
astatic lesions at the time of operation. This could be
achieved through overlapping image reconstruction with
helical computed tomography and accurate video-assisted
tumor resection with manual palpation of the entire lung,
such as a transxiphoid approach.4
In our series, resecting pulmonary metastases was not
worthwhile in patients who had hilar or mediastinal lymph
node metastases. We understand that pulmonary metastasis
with subsequent lymph node metastasis is part of the met-
astatic cascade.5 We have no evidence that hilar and medi-
astinal lymph node dissection can control disease. Evalua-
tion and sampling of hilar and mediastinal lymph nodes are
important for predicting the clinical course after thoracot-
omy and therefore should be attempted.6-8
Mediastinal or hilar lymph nodes were examined in 138
of our patients. The survival among patients with a lymph
node metastasis was worse than among those without. A
prospective study is required to investigate whether lymph
node dissection improves the survival of patients with a
pulmonary metastasis from colorectal carcinoma. However,
the presence of lymph node metastasis might be a possible
contraindication to surgical resection.7
An elevated CEA level greater than 10 ng/mL was a poor
prognostic finding in our series. Preoperative CEA levels do
appear to be a significant predictor of survival after resec-
tion of pulmonary metastases. Among our patients under-
going pulmonary metastasectomy, CEA levels correlated
with recurrence and reduction in overall patient survival.7
Serum CEA level is an indication of the total tumor mass
and the ability of tumor cell to express CEA.9 This antigen
is known to participate in intracellular recognition as well as
to promote adhesion of tumor cells to host cells, which
possibly explains the decreased survival.10
Traditional criteria for resection of colorectal pulmonary
metastases include absence of extrapulmonary disease.
However, in our series the presence of resectable metastatic
colorectal carcinoma in the liver was not associated with a
decreased survival; overall 5-year survival was identical to
that of patients without liver metastasis. We advocate com-
bined or staged surgical resection in carefully selected pa-
tients with solitary liver metastases before thoracotomy.
Although Thomford and coworkers2 excluded patients with
extrapulmonary metastases as candidates for thoracotomy,
there have been several reports about pulmonary resection
for patients with extrapulmonary metastases. McAfee and
colleagues11 said that the presence of resectable extrapul-
monary metastases before or at the time of thoracotomy was
not associated with a decreased survival. Yano,12 Regnard,9
Headrick,13 and their colleagues also reported that the pres-
ence of resectable or controllable hepatic metastases did not
decrease survival. The 5-year survival for patients who
underwent hepatic resection for metastases for colorectal
cancer ranged from 25% to 47.9% in these reports. These
results suggest that metastasectomy might be beneficial only
when the metastasis is confined to the liver—the first filter
for hematogenous metastases from the primary tumor—and
may have no effect when secondary metastasis from the first
filter organ occurs or when two filter organs, liver and lung,
are affected by different pathways, the portal and systemic
vein systems. In our series, the presence of hepatic metas-
tases was not an unfavorable prognostic factor. Our 26
patients with a solitary liver metastasis had a 5-year survival
of 34.1%. At present, it appears that patients with a solitary
pulmonary metastasis potentially benefit from pulmonary
resection even when there is a history of hepatic metastasis.
Several authors have advocated repeat thoracotomies for
TABLE 3. Multivariate prognostic factors analysis of the 165 patients according to Cox proportional hazards regression
model
Variable Hazard ratio 95% Confidence interval P value
Mode of operation
Unilateral or sequential 1 0.595-6.130 .2765
Bilateral (simultaneous) 1.910
Pulmonary metastases
Single 1 0.543-2.526 .6879
Multiple 1.171
Hilar or mediastinal lymph node
metastases
Positive 1 0.142-0.875 .0246
Negative 0.352
Prethoracotomy CEA
10 ng/mL 1 0.170-0.726 .0047
10 ng/mL 0.352
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recurrent pulmonary metastases.14 Our conclusion is simi-
lar. Survival among our patients who underwent a second
thoracotomy was satisfactory. Importantly, patients under-
going repeat thoracotomy had no increase in either morbid-
ity or mortality. Repeated metastasectomy for recurrent
pulmonary metastasis may be considered in patients without
a relapse in another site and with sufficient pulmonary
function. We therefore offer at least one repeat thoracotomy
to those selected patients who can tolerate further resection.
Conclusion
Pulmonary metastasectomy carries a potential survival ben-
efit for patients with metastatic colorectal carcinoma. In our
retrospective study, status of the hilar or mediastinal lymph
nodes and prethoracotomy CEA level were significant in-
dependent prognostic factors. Patients with pulmonary me-
tastases potentially benefit from pulmonary metastasectomy
even when there is a history of solitary liver metastasis.
Pulmonary metastasectomy is indicated for patients who
have a solitary liver metastasis if the metastasis has been
resected or treated before thoracotomy. Careful follow-up is
warranted, because patients with recurrent pulmonary me-
tastases can undergo repeat thoracotomy with acceptable
long-term survival. Repeated metastasectomy may be con-
sidered in patients without a relapse at another site and
sufficient pulmonary function. However, simultaneous bi-
lateral metastasectomy has no survival benefit to the patient.
Further prospective studies should be done to determine the
significance of this type of pulmonary metastasectomy.
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